CoChat

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

Open access
Vey, Norbert, Karlin, Lionel, Sadot-Lebouvier, Sophie, Broussais, Florence, Berton-Rigaud, Dominique, Rey, Jérôme, Charbonnier, Aude, Marie, Delphine, André, Pascale, Paturel, Carine, Zerbib, Robert, Bennouna, Jaafar, Salles, Gilles, Gonçalves, Anthony · 2018 · Oncotarget
Cited by 142

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Norbert Vey 1, 2 , Lionel Karlin 3 , Sophie Sadot-Lebouvier 4 , Florence Broussais 1 , Dominique Berton-Rigaud 4 , Jérôme Rey 1 , Aude Charbonnier 1 , Delphine Marie 5 , Pascale André 5 , Carine Paturel 5 , Robert Zerbib 5 , Jaafar Bennouna 4 , Gilles Salles 3 and Anthony Gonçalves 1, 2 1 Institut Paoli-Calmettes, Marseille, France 2 Aix-Marseille Université, Marseille, France 3 Centre Hospitalier Universitaire de Lyon Sud, Service d’Hématologie, Pierre Bénite, France 4 Institut de Cancérologie de l’Ouest–Site René Gauducheau, St Herblain, France 5 Innate Pharma, Marseille, France Correspondence to: Norbert Vey, email: veyn@ipc.unicancer.fr Keywords: monoclonal antibody; cancer immunotherapy; toxicity; natural killer cells Received: October 05, 2017 Accepted: March 02, 2018 Published: April 03, 2018 ABSTRACT Purpose: Anti-KIR monoclonal antibodies (mAbs) can enhance the antitumor responses of natural killer (NK) cells. We evaluated the safety of the anti-KIR2D mAb lirilumab in patients with various cancers. Experimental design: Thirty-seven patients with hematological malignancies ( n = 22) or solid tumors ( n = 15) were included in the study. Dose escalation (0.015 to 10 mg/kg) was conducted following a 3 + 3 design. Patients were scheduled to receive four cycles of treatment. In a second (extension) phase 17 patients were treated at 0.015 ( n = 9) or 3 mg/kg ( n = 8). Results: No dose-limiting toxicity was recorded. The most frequent lirilumab-related adverse events were pruritus (19%), asthenia (16%), fatigue (14%), infusion-related reaction (14%), and headache (11%), mostly mild or moderate. Pharmacokinetics was dose-dependent and linear, with minimal accumulation resulting from the 4-weekly repeated administrations. Full KIR occupancy (>95%) was achieved with all dosages, and the duration of occupancy was dose-related. No significant changes were observed in the number or distribution of lymphocyte subpopulations, nor was any reduction in the distribution of KIR2D-positive NK cells. Conclusions: This phase 1 trial demonstrated the satisfactory safety profile of lirilumab up to doses that enable full and sustained blockade of KIR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.24832

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 142

Metadata

Authors
Vey, N., Karlin, L., Sadot-Lebouvier, S., Broussais, F., Berton-Rigaud, D., Rey, J., Charbonnier, A., Marie, D., André, P., Paturel, C., Zerbib, R., Bennouna, J., Salles, G., & Gonçalves, A.
Venue
Oncotarget
Published
2018-04-03
Volume
9
Issue
25
Pages
17675-17688
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2795441690
Cited by
142
References
5
FWCI
6.89
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.